Testing Considerations for Novel Cell Substrates: A Regulatory Perspective

References

1. 1.↵
   1. Khan A. S.

   Regulatory considerations for raw materials used in biological products. PDA J. Pharm. Sci. Tech. 2010, 64 (5).
2. 2.↵
   http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm.
3. 3.↵
   Center for Biologics Evaluation and Research (CBER). Points to consider in the characterization of cell lines used to produce biologicals. US Food and Drug Administration, Rockville, MD; July 1993.
4. 4.↵
   CBER. Points to consider in the manufacture and testing of therapeutic products for human use derived from transgenic animals. Rockville, MD; January 1995.
5. 5.↵
   CBER. Points to consider in the manufacture and testing of monoclonal antibody products for human use. Rockville, MD; February 1997.
6. 6.↵
   CBER. Guidance for industry: Source animal, product, preclinical, and clinical issues concerning the use of xenotransplantation products in humans. April 2003.
7. 7.↵
   CBER. Guidance for industry: Supplemental guidance on testing for replication competent retrovirus in retroviral vector based gene therapy products and during follow-up of patients in clinical trials using retroviral vectors. November 2006.
8. 8.↵
   CBER. Guidance for industry: Characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications. Rockville, MD; February 2010.
9. 9.↵
   1. Griffiths E.

   Major issues associated with the use of cell substrates for the production of vaccines. Dev. Biol. (Basel) 2001, 106, 25–36.

   OpenUrlPubMed
10. 10.↵
    1. Hayflick L.

    A brief history of cell substrates used for the preparation of human biologicals. Dev. Biol. (Basel) 2001, 106, 5–24.

    OpenUrlPubMed
11. 11.↵
    1. Khan A. S.

    Characterization and qualification of cell substrates for manufacturing viral vaccines in the United States. BioProcessing J. 2009, 8 (3), 8–12.

    OpenUrl
12. 12.↵
    1. Hayflick L.

    History of cell substrates used for human biologicals. Dev. Biol. Stand. 1989, 70, 11–26.

    OpenUrlPubMed
13. 13.↵
    1. Hayflick L.,
    2. Hennessen W.

    1. Petricciani J. C.

    Cells, Science and Health. In Continuous Cell Lines as Substrates for Biologicals; Hayflick L., Hennessen W., Eds.: Dev. Biol. Standard, Karger: Basel, 1989; Vol. 70, pp 3–10.

    OpenUrl
14. 14.↵
    1. Horaud F.

    Absence of viral sequences in the WHO-VERO Cell Bank. A collaborative study. Dev. Biol. Stand. 1992, 76, 43–46.

    OpenUrlPubMed
15. 15.↵
    1. Swanson S. K.,
    2. Mento S. J.,
    3. Weeks-Levy C.,
    4. Brock B. D.,
    5. Kowal K. J.,
    6. Wallace R. E.,
    7. Ritchey M. B.,
    8. Cano F. R.

    Characterization of Vero cells. J. Biol. Stand. 1988, 16 (4), 311–320.

    OpenUrlPubMed
16. 16.↵
    Code of Federal Regulations, Title 21, Part 610. Food and Drugs, General Biological Products Standards. Office of the Federal Register, National Archives and Records Administration, U.S. Government Printing Office, Washington, DC. April 1, 2009.
17. 17.↵
    Code of Federal Regulations, Title 9, Animal and Animal Products (current year): Part 113.53, Requirements for ingredients of animal origin used for production of biologics. Office of the Federal Register, National Archives and Records Administration, U.S. Government Printing Office: Washington DC. January 1, 2010.
18. 18.↵
    International Conference on Harmonization. ICH Topics Q5D—Guidance on derivation and characterization of cell substrates used for production of biotechnological/biological products. 21 Sept 1998.
19. 19.↵
    International Conference on Harmonisation. ICH Topics Q5A(R1)—Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. 23 Sept 1999.
20. 20.↵
    World Health Organization (WHO). WHO Expert Committee on Biological Standardization, 47th Report: Requirements for the use of animal cells as in vitro substrates for the production of biologicals. WHO Technical Report Series, No. 878, annex 1. 1998.
21. 21.↵
    1. Khan A. S.,
    2. Ma W.,
    3. Ma Y. K.,
    4. Kumar A.,
    5. Williams D. K.,
    6. Muller J.,
    7. Ma H.,
    8. Galvin T. A.

    Proposed algorithm to investigate latent and occult viruses in vaccine cell substrates by chemical induction. Biologicals 2009, 37 (3), 196–201.

    OpenUrlPubMed
22. 22.↵
    1. Petricciani J.,
    2. Sheets R

    1. Raeber A. J.,
    2. Oesch B.

    Diagnostics for TSE agents. In Vaccine Cell Substrates; Petricciani J., Sheets R, Eds.; 2004. Dev. Biol. (Basel), Karger: Basel, 2006; Vol. 123, pp. 313–323.

    OpenUrl